Table 1.
The clinical data of CMV retinitis patients with AIDS before ganciclovir therapy and after ganciclovir therapy
| Patient | Age | Gender | CD4+ | Mode | Other | HIV VL | Log-HIV | CMV- | CMV- | CMV VL | Log-CMV | Vision Acuity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ID | (years) | Count | of | OI | (copies ml) | IgM | IgG | (copies/ml) | ||||
| (cells/μl) | transmission | |||||||||||
| 1 (bi) | 55 | M | 157 | S | TB | 1.78 × 103 | 7.48 | Neg | Pos | 2.37 × 103 | 7.77 | 20/25(R), 20/32(L) |
| 2 | 34 | M | 4 | B | PJP | 3.60 × 105 | 12.79 | Pos | Pos | Neg | NA | 20/32(L) |
| 3 | 46 | F | 20 | B | TB | 1.21 × 105 | 11.7 | Neg | Pos | Neg | NA | 20/50(L) |
| 4 | 37 | M | 6 | S | OFI,PFI | 2.16 × 105 | 12.28 | Neg | Pos | 6.24 × 103 | 8.74 | 20/63(L) |
| 5 (bi) | 33 | M | 53 | B | PFI | 5.11 × 102 | 6.24 | Neg | Pos | 3.65 × 103 | 8.20 | 20/63(R), 20/200(L) |
| 6 | 34 | M | 99 | B | N | 1.24 × 103 | 7.12 | Neg | Pos | 5.75 × 103 | 8.66 | 20/250(R) |
| 7 (bi) | 42 | M | 7 | S | HZ,PJP, | 1.71 × 104 | 9.75 | Neg | Pos | 8.57 × 103 | 9.06 | 20/200(R), 20/100(L) |
| 8 | 52 | M | 45 | U | TB | 6.10 × 105 | 13.32 | Neg | Pos | 2.51 × 103 | 7.83 | 20/25(R) |
| 9 (bi) | 26 | M | 28 | S | PC | 7.74 × 104 | 11.26 | Neg | Pos | 1.87 × 104 | 9.84 | 20/50(R), 20/50(L) |
| 10 | 48 | M | 5 | U | PJP | 1.67 × 104 | 9.72 | Neg | Pos | 1.23 × 105 | 11.72 | 20/50(R) |
| 11 (bi) | 25 | F | 3 | S | N | 1.80 × 105 | 12.1 | Neg | Pos | Neg | NA | 20/200(R), 20/20(L) |
| 12 | 35 | M | 28 | S | L,PI | 3.87 × 104 | 10.56 | Neg | Pos | 3.34 × 105 | 12.72 | 20/400(L) |
| 13 (bi) | 42 | M | 1 | U | FI | 1.10 × 106 | 13.91 | Neg | Pos | 1.08 × 105 | 11.59 | 20/50(R), HM/BE(L) |
| 14 (bi) | 34 | M | 97 | S | CM | 3.81 × 104 | 10.55 | Neg | Pos | 8.08 × 103 | 9.00 | 20/100(R), HM/BE(L) |
| 15 | 26 | M | 36 | S | N | 6.55 × 105 | 13.39 | Neg | Pos | 2.04 × 103 | 7.62 | HM/BE(L) |
| 16 (bi) | 25 | M | 5 | S | CMVM | 2.56 × 104 | 10.15 | Neg | Pos | 3.86 × 103 | 8.26 | LP (bi) |
| 17 (bi) | 33 | F | 3 | S | CNSI | 4.91 × 104 | 10.8 | Neg | Pos | 3.37 × 104 | 10.43 | 20/63(R), 20/100(L) |
| 18 | 73 | F | 17 | S | PJP | 6.64 × 105 | 13.41 | Neg | Pos | 1.31 × 103 | 7.18 | 20/200(L) |
| 19 (bi) | 59 | M | 16 | S | PJP | 1.89 × 105 | 12.15 | Neg | Pos | 6.50 × 106 | 15.69 | 20/200(R), 20/100(L) |
| 20 (bi) | 42 | M | 33 | S | FI | 2.06 × 103 | 7.63 | Neg | Pos | 1.69 × 106 | 14.34 | 20/200(R), HM/BE(L) |
| 21 | 30 | M | 0 | S | PJP | 2.73 × 105 | 12.52 | Neg | Pos | 3.64 × 105 | 12.80 | HM/BE(R) |
| 22 (bi) | 73 | M | 35 | S | PJP | 6.64 × 105 | 13.41 | Neg | Pos | 2.03 × 105 | 12.22 | NA |
| 23 | 59 | M | 30 | S | TB | 2.50 × 104 | 10.13 | Neg | Pos | 1.78 × 105 | 12.09 | 20/40(R) |
| Patient | Time | Time | response to anti-CMV | treatment/ | CMV VL | CD4+ Counts* | Vision Acuity* | |||||
| ID | HAART Received | Anti-CMV Received | treatment | complications | (copies/ml) | (cells/μl) | ||||||
| (weeks) | (weeks) | |||||||||||
| 1 (bi) | 72 | 4 | Effective | NO | Neg | 235 | 20/20(R), 20/20(L) | |||||
| 2 | 24 | 24 | Effective | NO | Neg | 58 | 20/20(L) | |||||
| 3 | 28 | 24 | Effective | NO | Neg | 248 | 20/20(L) | |||||
| 4 | 16 | 8 | Effective | IRU | Neg | 165 | 20/32(L) | |||||
| 5 (bi) | 40 | 28 | Effective | NO | Neg | 227 | 20/20(R), 20/25(L) | |||||
| 6 | 24 | 24 | Effective | NO | Neg | 400 | 20/20(R) | |||||
| 7 (bi) | 4 | 3 | Effective | IRU | Neg | 186 | 20/20(R), 20/20(L) | |||||
| 8 | 4 | 2 | Effective | NO | Neg | 460 | 20/20(R) | |||||
| 9 (bi) | 12 | 6 | Effective | NO | Neg | 177 | 20/32(R), 20/32(L) | |||||
| 10 | 8 | 2 | Effective | NO | Neg | 166 | 20/32(R) | |||||
| 11 (bi) | 8 | 8 | Effective | NO | Neg | 120 | 20/20(R), 20/20(L) | |||||
| 12 | 28 | 2 | Effective | NO | Neg | 121 | 20/32(L) | |||||
| 13 (bi) | 20 | 2 | Effective | NO | Neg | 189 | 20/25(R), 20/400(L) | |||||
| 14 (bi) | 12 | 12 | Effective | NO | Neg | Missing | 20/32(R),CF/50 cm(L) | |||||
| 15 | 24 | 16 | Effective | Rel, RD | Neg | 182 | 20/50(L) | |||||
| 16 (bi) | 20 | 8 | Effective | NO | Neg | 222 | HM/BE(R),CF/BE(L) | |||||
| 17 (bi) | 0* | 0* | NA | NA | NA | NA | NA | |||||
| 18 | 0* | 0* | NA | NA | NA | NA | NA | |||||
| 19 (bi) | 2 | 1.3 | NA | NA | NA | NA | NA | |||||
| 20 (bi) | 6 | 0* | NA | NA | NA | NA | NA | |||||
| 21 | 8 | 0* | NA | NA | NA | NA | NA | |||||
| 22 (bi) | 0* | 0* | NA | NA | NA | NA | NA | |||||
| 23 | 0* | 0* | NA | NA | NA | NA | NA | |||||
CD4+ count: CD4+ count when diagnosed CMV retinitis; CD4+ count*: CD4+ count when follow-up finished; Vision Acuity: vision acuity when diagnosed CMV retinitis; Vision Acuity*: vision acuity when follow-up finished; HM/BE: hand movement/before eye; LP: light perception; NA: not available; bi: bilatéral; HIV VL: HIV viral load; CMV VL: CMV viral load; F: female; M: male; S: sexually transmission; B: blood infusion; U: unknown; Other OI: other opportunistic infection; TB: tuberculosis; PJP: pneumocystis jiroveci pneumonia; OFI: oral fungal infection; PFI: pulmonary fungal infection; N: no other opportunistic infection but CMV retinitis; HZ: herpes zoster; PC: pancreatitis; L: lymphoma; PI: pulmonary infection; FI: fungal infection; CM: cryptococcal meningitis; CMVM: CMV myelitis; CNSI: central nervous system infection; Time ART received: the time of ART from beginning ART to ending the follow-up; Time Anti-CMV received: the time during anti-CMV treatment with ganciclovir; bi: bilateral; HIV VL: HIV viral load; CMV VL: CMV viral load; Log-HIV: Log-transform of HIV viral load; Log-CMV: Log-transform of CMV viral load; CF/50 cm: count finger/50 cm; HM/BE: hand movement/before eye; CF/BE: count finger/before eye; NA: not available; 0* indicated that the therapeutic regime was not started or less than one week and the patients were died shortly after admitted to the hospital; Rel: relapse; RD: retinal detachment; NO: no ocular complications